Analyst Actions: MSFT, BAC, UAL, ALA, ARBA, CMRC, More

Author:
Publish date:

ING Barings reiterated its strong buy on Microsoft (MSFT) - Get Report and a price target of 135.

Upgrades

Bank of America

(BAC) - Get Report

: UP to buy from hold at ING Barings; price target: 70.

Downgrades

United Airlines

parent

UAL

(UAL) - Get Report

: DOWN to hold from buy at ING Barings.

Initiations

Alcatel

(ALA)

: RESTARTED strong buy at

Morgan Stanley Dean Witter

.

Aurora Biosciences

(ABSC)

: NEW buy at

UBS Warburg

, price target: 70.

Ariba

(ARBA)

: NEW buy at

ABN Amro

.

Commerce One

(CMRC)

: NEW buy at ABN Amro.

LookSmart

(LOOK)

: NEW accumulate/buy at

Merrill Lynch

.

Salon.com

(SALN)

: 2001 revenue estimates DOWN to $14.3 million from $20.5 million and 2001 EPS estimate lowered at

WR Hambrecht

.

Group Moves

ING Barings commented on e-brokerage firms:

  • E*Trade (EGRP) : DOWN to hold from buy.
  • Charles Schwab (SCH) : second-quarter EPS view DOWN to 22 cents from 25 cents and full-year 2000 EPS estimate to 98 cents from $1.11.
  • Knight/Trimark (NITE) : price target DOWN to 47 from 65.

Merrill Lynch analyst Todd Nelson initiated coverage of the genomics and life science tools and technologies sector:

  • Invitrogen (IVGN) : at intermediate-term buy and long-term buy; price target: 63.
  • Techne (TECH) - Get Report at intermediate-term accumulate and long-term buy; price target: 87 1/2.
  • Celera Genomics (CRA) at intermediate-and long-term accumulate .
  • GeneLogic (GLGC) at intermediate-term neutral and long-term accumulate.
  • PE Biosystems (PEB) - Get Report at intermediate- and long-term buy; price target: 70.
  • CuraGen (CRGN) at intermediate-term accumulate and long-term buy.
  • Incyte Genomics (INCY) - Get Report at intermediate-term accumulate and long-term buy; price target: 75.